3.98

0.50% 0.010

Inovio Pharmaceuticals Inc (INO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Inovio Pharmaceuticals Inc stock is traded at $3.98, with a volume of 35,184. It is up +0.50% in the last 24 hours and down -30.49% over the past month. Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Previous Close:

$3.97

Open:

$4.01

24h Volume:

35,184

Relative Volume:

0.11

Market Cap:

$104.64M

Revenue:

$832.00K

Net Income/Loss:

$-135.12M

P/E Ratio:

-6.1231

EPS:

-0.65

Net Cash Flow:

$-124.69M

1W Performance:

-16.35%

1M Performance:

-30.49%

6M Performance:

-63.69%

1Y Performance:

-20.49%

1-Day Range:

$3.97

$4.03

1-Week Range:

$3.85

$4.97

52-Week Range:

$3.85

$14.75

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Name

Inovio Pharmaceuticals Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(858) 410-3134

Address

6769 MESA RIDGE RD., SAN DIEGO, PA

Employee

122

Twitter

@inoviopharma

Next Earnings Date

2024-11-07

Latest SEC Filings

INO's Discussions on Twitter

Compare INO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INO	3.98	104.64M	832.00K	-135.12M	-124.69M	-0.65
VRTX	447.51	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.90	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.12	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.68	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.20	24.49B	3.30B	-501.07M	1.03B	11.54

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-09-22	Downgrade	Maxim Group	Buy → Hold
Nov-01-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-19-22	Resumed	RBC Capital Mkts	Sector Perform
May-11-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-21-22	Upgrade	BofA Securities	Underperform → Neutral
Dec-29-21	Resumed	Jefferies	Hold
Sep-10-21	Downgrade	BofA Securities	Neutral → Underperform
Jun-24-21	Initiated	Jefferies	Hold
Mar-23-21	Initiated	BofA Securities	Neutral
Feb-12-21	Initiated	Oppenheimer	Outperform
Nov-17-20	Downgrade	ROTH Capital	Neutral → Sell
Nov-10-20	Upgrade	ROTH Capital	Sell → Neutral
Sep-28-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-28-20	Upgrade	Maxim Group	Hold → Buy
Jul-01-20	Downgrade	Maxim Group	Buy → Hold
Jul-01-20	Downgrade	ROTH Capital	Neutral → Sell
Jun-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-26-20	Downgrade	Stifel	Buy → Hold
May-21-20	Initiated	The Benchmark Company	Buy
Apr-30-20	Downgrade	ROTH Capital	Buy → Neutral
Mar-13-20	Downgrade	Piper Sandler	Overweight → Neutral
Mar-13-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-19-19	Initiated	ROTH Capital	Buy
Feb-15-18	Reiterated	Maxim Group	Buy
Oct-18-17	Initiated	RBC Capital Mkts	Outperform
Sep-06-17	Initiated	Citigroup	Buy
Jun-08-17	Upgrade	Piper Jaffray	Neutral → Overweight
May-24-17	Reiterated	Maxim Group	Buy
Mar-16-17	Upgrade	Maxim Group	Hold → Buy
Mar-16-17	Downgrade	Piper Jaffray	Overweight → Neutral

View All

Inovio Pharmaceuticals Inc Stock (INO) Latest News

Nov 20, 2024

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Nov 20, 2024

INOVIO Set to Unveil Q3 2024 Financial Results and Business Insights on November 14! - MSN

Nov 20, 2024

July 25, 2024 - Site Selection Magazine

Nov 20, 2024

What is HC Wainwright's Estimate for INO FY2024 Earnings? - MarketBeat

Nov 20, 2024

Nov 19, 2024

Inovio Pharmaceuticals (LTS:0A43) Debt-to-Equity : 0.13 (As of Jun. 2024) - GuruFocus.com

Nov 19, 2024

Inovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Nov 19, 2024

INOVIO Reports Third-Quarter Financial Results and Updates on INO-3107 Progress - MyChesCo

Nov 19, 2024

Nov 18, 2024

The Analyst Landscape: 4 Takes On Inovio Pharmaceuticals - Benzinga

Nov 18, 2024

Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat

Nov 18, 2024

INOVIO Announces Promising Immunology Data for INO-3107 in RRP Treatment - MyChesCo

Nov 18, 2024

Inovio stock hits 52-week low at $4.15 amid market challenges - Investing.com Nigeria

Nov 18, 2024

Inovio Pharmaceuticals (NASDAQ:INO) Given New $15.00 Price Target at Oppenheimer - MarketBeat

Nov 18, 2024

Inovio shares target cut by Oppenheimer, retains outperform on Q3 results - Investing.com UK

Nov 18, 2024

Nov 17, 2024

Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish - MSN

Nov 17, 2024

Inovio focused on launching global COVID-19 vaccine trial next month - The Jerusalem Post

Nov 17, 2024

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 17, 2024

Nov 16, 2024

Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023) - Yahoo Finance

Nov 16, 2024

Inovio to begin mid-stage study of COVID-19 vaccine candidate - Reuters

Nov 16, 2024

Nov 15, 2024

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Nov 15, 2024

Royal Bank of Canada Cuts Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $6.00 - MarketBeat

Nov 15, 2024

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Inovio: Q3 Earnings Snapshot - mySA

Nov 15, 2024

Q3 2024 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com

Nov 15, 2024